• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Johnson & Johnson - Articles and news items

globe-pill

GSK tops list ranking big pharma’s global access to medicine

Industry news / 14 November 2016 / Niamh Louise Marriott, Digital Content Producer

Read how the 2016 Access to Medicine Index ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries…

rheumatoid-arthritis

Janssen submits EU application for rheumatoid arthritis drug

Industry news / 16 September 2016 / Niamh Louise Marriott, Digital Content Producer

Sirukumab is a human monoclonal IgG1 kappa antibody that targets the cytokine IL-6, a protein believed to play a role in autoimmune rheumatoid arthritis…

esketamine depression drug

FDA grants breakthrough therapy designation for depression drug

Industry news / 16 August 2016 / Janssen

Following succesful phase II trials, the FDA have granted a Breakthrough Therapy Designation for esketamine, an investigational antidepressant medication…

antimicrobial resistance

Pharma calls for collective action to combat antimicrobial resistance

Industry news / 21 January 2016 / Victoria White

More than 80 companies and organisations have signed the Declaration on Combating Antimicrobial Resistance (AMR), an industry-wide call to action…

hiv

J&J announces new global commitments to end HIV infection in girls and women

Industry news / 2 December 2015 / Victoria White

Johnson & Johnson has announced four new public-private partnerships to significantly reduce the burden of HIV incidence, especially among adolescent girls…

novira

Johnson & Johnson to acquire Novira Therapeutics

Industry news / 5 November 2015 / Victoria White

The acquisition includes Novira’s portfolio of novel antivirals, including its lead candidate, NVR 3-778…

7th Global Healthcare Conference

7th Global Healthcare Conference

Supplier news / 3 November 2015 / London Business School

The Future of Healthcare – striking a balance between patients, value and innovation. Monday 7 December 2015…

axspa

J&J and Norvatis to fight it out in the axSpA treatment space

Industry news / 22 July 2015 / Victoria White

Stelara has progressed into Phase III development for axSpA and, following its anticipated approval, is forecast to achieve sales of $244.7 million in 2024…

schizophrenia

Johnson & Johnson and collaborators launch the Open Translational Science Project in Schizophrenia

Industry news / 9 June 2015 / Victoria White

Johnson & Johnson and a group of leading research organisations are launching the OPTICS Project – Open Translational Science in Schizophrenia…

cordis

J&J accepts binding offer from Cardinal Health for Cordis

Industry news / 28 May 2015 / Victoria White

Johnson & Johnson has accepted the 1 March 2015 binding offer from Cardinal Health to acquire its Cordis business for an approximate value of $2 billion…

compassionate-use-johnson

Johnson & Johnson announces groundbreaking partnership to evaluate compassionate use requests of investigational medicines

Industry news / 7 May 2015 / Victoria White

J&J has announced a first-of-its-kind partnership that enlists a third party to review compassionate use requests made for investigational medicines…

Johnson & Johnson

Johnson & Johnson tops IDEA Pharma’s Productive Innovation Index for the third consecutive year

Industry news / 27 February 2015 / IDEA Pharma

Now in its fifth year, the Productive Innovation Index (PII) celebrates the top 30 pharmaceutical companies most effective at developing and commercialising new medicines – bringing innovations to market successfully…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +